Cambridge Investment Research Advisors’s Akebia Therapeutics AKBA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14K	Sell	12,219 -3,690	-23%	-$4.39K	﹤0.01%	3753
2026 Q1	$22K	Hold	15,909	–	–	﹤0.01%	3889
2025 Q4	$26K	Sell	15,909 -3,890	-20%	-$8.14K	﹤0.01%	3782
2025 Q3	$54K	Buy	+19,799	New	+$65.9K	﹤0.01%	3652

Other funds holding AKBA

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

AHL

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

PWP

Parkwoods Wealth Partners Syracuse, New York $622M AUM 24.36% 1-Year Est. Return

OBWG

Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Cambridge Investment Research Advisors's AKBA Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Akebia Therapeutics (AKBA) stake by 23% in Q2 2026, selling an estimated $4.39K and leaving 12,219 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3753.

Cambridge Investment Research Advisors first reported a position in AKBA in Q3 2025 and has held it in 4 quarters since. The position peaked at $54K in Q3 2025. 27 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Cambridge Investment Research Advisors held 12,219 shares of Akebia Therapeutics worth $14K as of Q2 2026.
Cambridge Investment Research Advisors sold 3,690 Akebia Therapeutics shares in Q2 2026, an estimated $4.39K.
Akebia Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3753 holding.
Cambridge Investment Research Advisors first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 4 quarters since.
Cambridge Investment Research Advisors's Akebia Therapeutics position peaked at $54K in Q3 2025.
27 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.